Sponsor: University of Oxford
EudraCT number: 2009-018153-23

EudraCT number: 2004-003836-77
Sponsor: University of Oxford
Funded by: Cancer Research UK
Esomeprazole supplied by: Astra Zeneca

Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma – A randomised Phase III trial. 

The study has received a favourable opinion from ethics.

To determine the effect of adding WBRT to local treatment on distant intracranial control (primary), quality of life (QoL), performance status, neurocognitive function (NCF) and overall survival.

Sponsor: University of Oxford
EudraCT number: 2014-000514-61

A Proof of Concept Study to Investigate the Feasibility of Targeted Release of Doxorubicin from Lyso-thermosensitive Liposomal (LTSL) Doxorubicin (ThermoDox®) Using Focused Ultrasound in Patients with Primary or Secondary Liver Tumours.

​Sponsor: University of Oxford
ClinicalTrials.gov Number: NCT02308722
UKCRN ID: 18496

Stereotactic Body Radiotherapy (SBRT) pre-operatively for pancreatic cancer: A Phase I trial of pre-operative, margin intensive, stereotactic body radiation therapy for pancreatic cancer.

Study Design

Phase I rolling six design dose escalation study testing the use of Stereotactic Body Radiation Therapy (SBRT) delivered in the pre-operative setting for pancreatic cancers.

Sponsor: University of Oxford
Funded by: CRUK EPSRC Oxford Cancer Imaging Centre

RHYTHM-I: modulation of Radiotherapy according to HYpoxia: exploiting changes in the Tumour Microenvironment to improve outcome in rectal cancer

Study Status

Closed to recruitment

Many thanks to the trial team at the Churchill Hospital for their efforts during the trial.

This is a single-centre study at the Churchill Hospital, Oxford.

Target recruitment: 15 patients (5 in Group A and 10 in Group B)